NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chain

NITI Aayog's Trade Watch Quarterly report (June 2026) proposed a standardised pharmaceutical chapter as a mandatory component in all future Free Trade Agreem...

What Happened

NITI Aayog's Trade Watch Quarterly report (June 2026) proposed a standardised pharmaceutical chapter as a mandatory component in all future Free Trade Agreements (FTAs) that India negotiates.
The blueprint recommends including provisions for regulatory harmonisation, intellectual property predictability, patent dispute timelines, and mutual recognition of Good Manufacturing Practices (GMP) standards.
The report calls for enhanced industry-academia linkages to accelerate patent commercialisation and build startup incubation ecosystems around drug discovery.
NITI Aayog flagged India's lag in biologics, vaccines, and advanced therapies — even as it leads globally in generics — as a structural gap that proactive FTA architecture can help close.
The think tank recommended restricting pharmaceutical patent oppositions to defined, transparent timelines to improve regulatory predictability for trading partners and foreign investors.

Static Topic Bridges

NITI Aayog: Mandate and Policy Instruments

The National Institution for Transforming India (NITI Aayog) was established on January 1, 2015, replacing the Planning Commission. Unlike its predecessor, which had fund-allocation authority, NITI Aayog is a policy think-tank that provides strategic and technical advice to the Union Government. Its mandates include fostering cooperative federalism, providing directional and policy inputs to Ministries, and producing sector-specific research such as the Trade Watch Quarterly.

NITI Aayog does not have statutory authority; its recommendations are advisory, requiring Cabinet or Ministry-level adoption.
The Trade Watch Quarterly is a NITI Aayog publication analysing India's external trade trends and policy gaps.
The Governing Council of NITI Aayog is chaired by the Prime Minister; it includes all State Chief Ministers and Lt. Governors.

Connection to this news: The pharma FTA chapter proposal originates from NITI Aayog's advisory function — it frames a negotiating template for the Commerce Ministry to adopt in ongoing and future FTA talks with the UK, EU, and the US.

Free Trade Agreements and the Pharmaceutical Sector

FTAs increasingly include dedicated chapters for specific sectors beyond goods tariffs. A pharmaceutical chapter in a trade agreement typically covers: tariff elimination on drugs, APIs, and medical devices; regulatory harmonisation (alignment of drug approval standards); intellectual property protections (patent term extensions, data exclusivity); and mechanisms for mutual recognition of manufacturing quality standards (GMP equivalence).

The Trans-Pacific Partnership (TPP/CPTPP) and the US-Korea FTA (KORUS) contain detailed pharmaceutical and intellectual property chapters that set global benchmarks.
India has historically resisted strong IP provisions in FTAs, particularly "TRIPS-plus" obligations (e.g., data exclusivity, patent linkage, evergreening protections) that could delay generic drug entry.
"Patent linkage" — linking drug regulatory approval to patent status — is a TRIPS-plus demand often included in US FTA templates that India has resisted.
TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) under the WTO mandates minimum IP standards; TRIPS-plus goes beyond these minimums.

Connection to this news: NITI Aayog's proposal for a pharma chapter attempts to balance India's need for IP predictability to attract innovation investment against its historical commitment to affordable generics — finding a middle path distinct from either TRIPS-plus or bare TRIPS compliance.

India's Patent Law and Compulsory Licensing

India's Patents Act, 1970, as amended by the Patents (Amendment) Act, 2005 (following TRIPS compliance), includes distinctive provisions that reflect public health priorities. Section 3(d) bars "evergreening" — it prohibits patenting of new forms of known substances unless they show significantly enhanced efficacy. Section 84 allows compulsory licensing: any person can apply to the Controller General of Patents to work a patent if the patented invention is not available at a reasonably affordable price.

Section 3(d) was the basis of the landmark Novartis vs. Union of India (2013) Supreme Court ruling, which upheld rejection of a patent on Gleevec (imatinib), a cancer drug.
India granted its first compulsory licence in 2012 (Natco Pharma vs. Bayer AG) for cancer drug Sorafenib, reducing patient cost from ₹2.8 lakh/month to ₹8,800/month.
Pre-grant and post-grant patent oppositions under Sections 25(1) and 25(2) of the Patents Act are mechanisms unique to India's system that allow third parties to challenge pharmaceutical patents.
NITI Aayog's proposal to cap opposition timelines addresses a long-standing trading partner complaint that India's opposition proceedings create excessive uncertainty.

Connection to this news: NITI Aayog's pharma FTA chapter must navigate around India's public health-protective patent provisions. The proposal to standardise opposition timelines (rather than eliminate them) reflects a calibrated attempt to improve investor confidence without surrendering generic-access safeguards.

Industry-Academia Interface and Patent Commercialisation

India's pharmaceutical sector is characterised by strong manufacturing competence but weak drug discovery infrastructure. Indian pharmaceutical companies invest roughly 7% of net sales in R&D, compared with 15–20% for global innovator companies. The gap between academic research outputs (patent filings) and commercial drug development is a persistent structural weakness — most patents filed by Indian universities and research institutions do not reach the market.

Indian pharmaceutical patent filings increased eightfold between 2013 and 2025, but commercialisation rates remain low due to weak industry-academia technology transfer mechanisms.
The Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Science and Technology (DST) support early-stage drug research, but late-stage development finance is limited.
The National Biopharma Mission (launched 2017) and the Biopharma Shakti scheme are government initiatives to bridge the drug-discovery-to-market gap.

Connection to this news: NITI Aayog's call for startup incubation and patent commercialisation infrastructure within the FTA pharma chapter context is aimed at positioning India as a drug-discovery hub, not just a drug-manufacturing one — a shift that would command higher value-added exports in FTA partner markets.

Key Facts & Data

NITI Aayog was established January 1, 2015, replacing the Planning Commission.
India's R&D spend in pharma: ~7% of net sales vs. 15–20% for global innovators.
India's pharmaceutical patent filings rose 8x from 2013 to 2025.
Section 3(d) of the Patents Act bars evergreening; upheld by the Supreme Court in Novartis vs. Union of India (2013).
India's first compulsory licence (2012): Sorafenib (Bayer) — cost reduced from ₹2.8 lakh to ₹8,800 per month.
TRIPS-plus provisions (data exclusivity, patent linkage) remain a consistent US demand that India has resisted in bilateral negotiations.
India has active FTA negotiations ongoing with the UK, EU, and (interim) the US as of 2026.
India's pharma exports: approximately $35.8 billion annually; global share only 2.8% of $1.3 trillion market.